ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

11/4/24 4:15:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORIC alert in real time by email

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November:

Guggenheim's Inaugural Healthcare Innovation Conference – Participating in a fireside chat on Monday, November 11, 2024, at 10:30 a.m. ET
Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 21, 2024, at 12:00 p.m. GMT

Live webcasts of the discussions will be available through the investor section of the company's website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC^® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer

[email protected]

[email protected]

Get the next $ORIC alert in real time by email

Recent Analyst Ratings for

$ORIC

Date	Price Target	Rating	Analyst
10/31/2024	$20.00	Overweight	Wells Fargo
9/6/2024	$20.00	Buy	Stifel
2/23/2024		Overweight	Cantor Fitzgerald
9/22/2023	$8.00	Outperform	Wedbush
3/23/2023	$16.00	Neutral → Buy	H.C. Wainwright
3/21/2023	$15.00	Neutral → Buy	Guggenheim
3/16/2023	$14.00	Perform → Outperform	Oppenheimer
7/18/2022		Perform	Oppenheimer

More analyst ratings

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $ORIC

$ORIC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wells Fargo initiated coverage on ORIC Pharmaceuticals with a new price target

Stifel initiated coverage on ORIC Pharmaceuticals with a new price target

Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals

$ORIC SEC Filings

SEC Form 10-Q filed by Oric Pharmaceuticals Inc.

Oric Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by Oric Pharmaceuticals Inc.

$ORIC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director You Angie

SEC Form 4 filed by Director Kunkel Lori Anne

SEC Form 4 filed by Director Hoerter Steven L.

$ORIC Leadership Updates

Live Leadership Updates

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

$ORIC Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc. (Amendment)

$ORIC Market Insights

Live Market Insights

Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

ORIC Pharmaceuticals Says Entered Into Clinical Trial Collaboration And Supply Agreements With Bayer And Johnson & Johnson

$ORIC Financials

Live finance-specific insights

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

$ORIC Press Releases

Fastest customizable press release news feed in the world

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Recent Analyst Ratings for
$ORIC

$ORIC
Analyst Ratings

$ORIC
SEC Filings

$ORIC
Insider Trading

$ORIC
Leadership Updates

$ORIC
Large Ownership Changes

$ORIC
Market Insights

$ORIC
Financials

$ORIC
Press Releases